Literature DB >> 273259

Erythroid colony formation from human fetal liver.

P T Rowley, B M Ohlsson-Wilhelm, B A Farley.   

Abstract

The liver of the human fetus, induced to abort by prostaglandin or by hypertonic saline, contains cells that form colonies in methylcellulose in vitro. The colonies are erythroid as identified by cellular staining of hemoglobin by benzidine. Colony formation is generally similar, with regard to number, size and time of development, to that observed in cultures of nonadherent cells from human adult marrow. The number of colonies observed increases with the concentration of erythropoietin used and with the concentration of cells plated and decreases with the time interval between intra-amniotic instillation of the inducing agent and culture. Colong number is not greatly influenced by fetal age in the period 16-20 weeks or by whether the inducing agent is prostaglandin or hypertonic saline. Prostaglandin- and hypertonic saline-induced abortuses thus provide an abundant source of human fetal erythroid tissue for morphologic and biochemical studies of erythroid development.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 273259      PMCID: PMC411384          DOI: 10.1073/pnas.75.2.984

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS.

Authors:  L HAYFLICK
Journal:  Exp Cell Res       Date:  1965-03       Impact factor: 3.905

Review 2.  Regulation of fetal hemoglobin production.

Authors:  H H Kazazian
Journal:  Semin Hematol       Date:  1974-10       Impact factor: 3.851

3.  The effect of erythropoietin on colonial growth of erythroid precursor cells in vitro.

Authors:  M C Cooper; J Levy; L N Cantor; P A Marks; R A Rifkind
Journal:  Proc Natl Acad Sci U S A       Date:  1974-05       Impact factor: 11.205

Review 4.  The current status of prostaglandins as abortifacients.

Authors:  W E Brenner
Journal:  Am J Obstet Gynecol       Date:  1975-10-01       Impact factor: 8.661

5.  Human marrow cells capable of erythropoietic differentiation in vitro: definition of three erythroid colony responses.

Authors:  C J Gregory; A C Eaves
Journal:  Blood       Date:  1977-06       Impact factor: 22.113

6.  Haemoglobin synthesis in human fetal liver maintained in short-term tissue culture.

Authors:  M Shchory; D J Weatherall
Journal:  Br J Haematol       Date:  1975-05       Impact factor: 6.998

7.  The placental and fetal response to the intra-amniotic injection of prostaglandin F2alpha in midtrimester abortions.

Authors:  P Jouppila; O Ylikorkala; P Karovonen; J Haapalahti; L Suonoja
Journal:  Br J Obstet Gynaecol       Date:  1976-04

8.  Replicative life-span of cultivated human cells. Effects of donor's age, tissue, and genotype.

Authors:  G M Martin; C A Sprague; C J Epstein
Journal:  Lab Invest       Date:  1970-07       Impact factor: 5.662

9.  Effects of testosterone and erythropoietin on erythroid colony formation in human bone marrow cultures.

Authors:  Y Moriyama; J W Fisher
Journal:  Blood       Date:  1975-05       Impact factor: 22.113

10.  Characterization of an erythroid precursor cell of high proliferative capacity in normal human peripheral blood.

Authors:  B J Clarke; D Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1977-03       Impact factor: 11.205

View more
  9 in total

1.  Characterization of hepatic progenitors from human fetal liver using CD34 as a hepatic progenitor marker.

Authors:  Parveen Nyamath; Ayesha Alvi; Aejaz Habeeb; Sanjeev Khosla; Aleem A Khan; C M Habibullah
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

2.  Purification of fetal hematopoietic progenitors and demonstration of recombinant multipotential colony-stimulating activity.

Authors:  S G Emerson; C A Sieff; E A Wang; G G Wong; S C Clark; D G Nathan
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

3.  Hemoglobin synthesis in cultures of hepatic erythroid cells from the human fetus.

Authors:  P T Rowley; B Ohlsson-Wilhelm; B A Farley; B Kosciolek
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

4.  Hematopoietic differentiation of human embryonic stem cells progresses through sequential hematoendothelial, primitive, and definitive stages resembling human yolk sac development.

Authors:  Elias T Zambidis; Bruno Peault; Tea Soon Park; Fred Bunz; Curt I Civin
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

5.  Characterization of hepatic progenitors from human fetal liver during second trimester.

Authors:  Mekala-Subba Rao; Aleem-Ahmed Khan; Nyamath Parveen; Mohammed-Aejaz Habeeb; Chittoor-Mohammed Habibullah; Gopal Pande
Journal:  World J Gastroenterol       Date:  2008-10-07       Impact factor: 5.742

6.  Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells.

Authors:  Elias T Zambidis; Tea Soon Park; Wayne Yu; Ada Tam; Michal Levine; Xuan Yuan; Marina Pryzhkova; Bruno Péault
Journal:  Blood       Date:  2008-08-26       Impact factor: 22.113

7.  Human embryonic hemopoiesis. Kinetics of progenitors and precursors underlying the yolk sac----liver transition.

Authors:  G Migliaccio; A R Migliaccio; S Petti; F Mavilio; G Russo; D Lazzaro; U Testa; M Marinucci; C Peschle
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

8.  Human fetal liver cultures support multiple cell lineages that can engraft immunodeficient mice.

Authors:  Marina E Fomin; Ashley I Beyer; Marcus O Muench
Journal:  Open Biol       Date:  2017-12       Impact factor: 6.411

9.  The adult livers of immunodeficient mice support human hematopoiesis: evidence for a hepatic mast cell population that develops early in human ontogeny.

Authors:  Marcus O Muench; Ashley I Beyer; Marina E Fomin; Rahul Thakker; Usha S Mulvaney; Masato Nakamura; Hiroshi Suemizu; Alicia Bárcena
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.